Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. The company was the target of an analyst price ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.68% at $6.43. This change lagged the S&P 500's 0.78% gain on the day. Elsewhere, the Dow gained 1.14%, while the tech-heavy ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals, Inc. before investing. In this article, we go over a ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...